Literature DB >> 3497054

Sequential changes in antibody levels to the env and gag antigens in human immunodeficiency virus infected subjects.

N Manca, F di Marzo Veronese, D D Ho, R C Gallo, M G Sarngadharan.   

Abstract

Sera from 51 HTLV-III (human immunodeficiency virus, HIV)-antibody positive subjects consisting of 21 asymptomatic individuals and 15 ARC and 15 AIDS patients were analyzed for their serological profiles toward the viral antigens. One of the asymptomatic subjects only showed a p24 reactivity in the immunoblot, but antibodies to the env antigens were clearly identified by immunoprecipitation of viral antigens (RIP) followed by SDS-polyacrylamide gel electrophoresis. RIP patterns of different subjects and even different bleeds from the same subjects showed a varying reactivity to the gag antigens whereas the reactivity towards the env antigens appeared to be generally stable. RIP analysis of sequential sera of virus-infected individuals indicated a pattern consistent with an initial steady rise of antibody reactivities to the gag antigens relative to the reactivities to the envelope antigens. These reactivities reached a plateau and then slowly declined. While all sera tested had antibodies to the envelope antigens gp160, gp120 and gp41, 86% of the asymptomatic subjects, 67% of the ARC patients and only 33% of the AIDS patients had antibodies to the gag proteins p24 and pr53gag.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497054     DOI: 10.1007/BF00239745

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  18 in total

1.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

2.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

3.  Classification of HTLV-III/LAV-related diseases.

Authors:  H W Haverkos; M S Gotlieb; J Y Killen; R Edelman
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

4.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

7.  Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals.

Authors:  K S Steimer; K W Higgins; M A Powers; J C Stephans; A Gyenes; C George-Nascimento; P A Luciw; P J Barr; R A Hallewell; R Sanchez-Pescador
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

8.  The epidemiology of AIDS: current status and future prospects.

Authors:  J W Curran; W M Morgan; A M Hardy; H W Jaffe; W W Darrow; W R Dowdle
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

9.  Primary human T-lymphotropic virus type III infection.

Authors:  D D Ho; M G Sarngadharan; L Resnick; F Dimarzoveronese; T R Rota; M S Hirsch
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  5 in total

1.  Challenges of antibody-mediated protection against HIV-1.

Authors:  George K Lewis
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

2.  Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.

Authors:  G Schmidt; K Amiraian; H Frey; J Wethers; R W Stevens; D S Berns
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

3.  Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.

Authors:  B C Nair; G Ford; V S Kalyanaraman; M Zafari; C Fang; M G Sarngadharan
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

4.  High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.

Authors:  Jörg Schüpbach; Leslie R Bisset; Stephan Regenass; Philippe Bürgisser; Meri Gorgievski; Ingrid Steffen; Corinne Andreutti; Gladys Martinetti; Cyril Shah; Sabine Yerly; Thomas Klimkait; Martin Gebhardt; Franziska Schöni-Affolter; Martin Rickenbach; J Barth; M Battegay; E Bernascon; J Böni; H C Bucher; P Bürgisser; C Burton-Jeangros; A Calmy; M Cavassini; R Dubs; M Egger; L Elzi; J Fehr; M Fischer; M Flepp; P Francioli; H Furrer; C A Fux; M Gorgievski; H Günthard; B Hasse; H H Hirsch; B Hirschel; I Hösli; C Kahlert; L Kaiser; O Keiser; C Kind; T Klimkait; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; N Müller; D Nadal; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; P Schmid; D Schultze; F Schöni-Affolter; J Schüpbach; R Speck; P Taffé; A Telenti; A Trkola; P Vernazza; V von Wyl; R Weber; S Yerly
Journal:  BMC Infect Dis       Date:  2011-09-26       Impact factor: 3.090

5.  Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.

Authors:  Jörg Schüpbach; Martin D Gebhardt; Zuzana Tomasik; Christoph Niederhauser; Sabine Yerly; Philippe Bürgisser; Lukas Matter; Meri Gorgievski; Rolf Dubs; Detlev Schultze; Ingrid Steffen; Corinne Andreutti; Gladys Martinetti; Bruno Güntert; Roger Staub; Synove Daneel; Pietro Vernazza
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.